Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL310 OLE in MPS II
NCT06075537Phase 3Enrolling by invitation
- Sponsor
- Denali Therapeutics Inc.
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 14
01
Overview
Phase 3, open-label trial of tividenofusp alfa in mucopolysaccharidosis type 2 (7 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence and intensity of treatment-emergent adverse events at 5 years, Clinically significant changes in urine total glycosaminoglycan concentrations at 5 years and 1 more. Started Sep 2023; status: enrolling by invitation.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NCT06075537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075537.